UNITUXIN (dinutuximab) injection

Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. FDA approved dinutuximab (brand name UNITUXIN) is not (yet) registered or available in India but on request Indian patient can buy UNITUXIN at the lowest price.

Home | (dinutuximab) injection

UNITUXIN (dinutuximab) injection Price In India and Overseas
UNITUXIN (dinutuximab) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

UNITUXIN (dinutuximab) injection

Dinutuximab is approved to be used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis retinoic acid to treat: Neuroblastoma.

Unituxin A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has gotten better with other anticancer treatment. Unituxin binds to a substance called GD2, which is found on some types of cancer cells. Unituxin may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Ch14.18, dinutuximab, MOAB Ch14.18, and monoclonal antibody Ch14.18.

Dinutuximab, A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has gotten better with other anticancer treatment. Dinutuximab binds to a substance called GD2, which is found on some types of cancer cells. Dinutuximab may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Ch14.18, MOAB Ch14.18, monoclonal antibody Ch14.18, and Unituxin.

Drug (Brand / Generic): UNITUXIN / dinutuximab
Current Indications: neuroblastoma
Marketed by:: United Therapeutics Corp
Approval Date: 2015

Available as (Form & Strength): Injection: 17.5 mg/5 mL (3.5 mg/mL) in a single-use via

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.